These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Highlights strong Vibegron results in older men & real-world prostate cancer insights
With standout ADC and t-cell engager response data across hard-to-treat cancers
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
Pharma giant targets new standards of care
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
